Oncothyreon, Inc. (NASDAQ:ONTY) reported Q1 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12). As of March 31, 2014, Oncothyreon’s cash, cash equivalents and investments were $64.3 million, compared to $72.6 million at December 31, 2013, a decrease of $8.3 million, or 11.4 percent. The decrease was primarily attributable to $8.0 million of cash used in operations during the quarter ended March 31, 2014. Oncothyreon Inc. (USA) (NASDAQ:ONTY) shares after opening at $2.64 moved to $2.88 on last trade day and at the end of the day closed at $2.85. Company price to sales ratio in past twelve months was calculated as – and price to cash ratio as 3.36. Oncothyreon Inc. (USA) (NASDAQ:ONTY) showed a positive weekly performance of 2.52%.
Corcept Therapeutics Incorporated (NASDAQ:CORT) announced it will report first quarter financial results and provide a corporate update on May 7, 2014. The Company will also host a conference call that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). Corcept Therapeutics Incorporated (NASDAQ:CORT) shares advanced 5.06% in last trading session and ended the day on $4.15. CORT return on equity ratio is recorded as -128.50% and its return on assets is -60.90%. Corcept Therapeutics Incorporated (NASDAQ:CORT) yearly performance is 134.46%.
Omeros Co. logo Omeros (NASDAQ:OMER) had its price objective raised by Needham & Company LLC from $15.00 to $17.00 in a research report released on Monday morning, Stock Ratings Network reports. Omeros Corporation (NASDAQ:OMER) shares moved up 7.20% in last trading session and was closed at $13.25, while trading in range of $12.15 – $13.25. Omeros Corporation (NASDAQ:OMER) year to date (YTD) performance is 17.36%.
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, on 1 may reported financial results for the 3 months ended March 31, 2014, and also provided an overview of recent accomplishments and upcoming milestones for its clinical development programs. CytRx Corporation (NASDAQ:CYTR) weekly performance is 11.96%. On last trading day company shares ended up $3.37. CytRx Corporation (NASDAQ:CYTR) distance from 50-day simple moving average (SMA50) is -17.43%. Analysts mean target price for the company is $11.00.
Leave a Reply